Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | PRCP | P42785 | 8/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30734419 | 1.00 | ACP3 (0.56) | ACP3TSHRNPSR1PRCPGAA | |
| SCHEMBL10384045 | 0.72 | OPRM1 (0.53) | PRCPGAAOPRM1SLC22A1SMN1; SMN2 | |
| SCHEMBL17187255 | 0.72 | TSHR (0.46) | ACP3TSHRNPSR1PRCPGAA | |
| SCHEMBL358171 | 0.72 | PRCP (0.58) | TSHRNPSR1PRCPGAAMAPT | |
| SCHEMBL30924714 | 0.72 | PRCP (0.58) | TSHRNPSR1PRCPGAAMAPT | |
| SCHEMBL1319681 | 0.72 | PRCP (0.58) | TSHRNPSR1PRCPGAAOPRM1 | |
| SCHEMBL4022286 | 0.71 | TSHR (0.75) | TSHRNPSR1PRCPGAAOPRM1 | |
| SCHEMBL95058 | 0.71 | PRCP (0.53) | TSHRNPSR1PRCPGAAOPRM1 | |
| SCHEMBL24017043 | 0.71 | PRCP (0.70) | TSHRNPSR1PRCPGAAMAPT | |
| SCHEMBL16799768 | 0.71 | PRCP (0.70) | TSHRNPSR1PRCPGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1227803-B1 | COMPOUNDS FOR INHIBITING IAPP-ASSOCIATED AMYLOID DEPOSITS | BELLUS HEALTH INTERNATIONAL LTD (CH) | 2010-05-05 | — | — | EP | claimed |
| CN-100435785-C | Pharmaceutical use of IAPP inhibiting compounds or pharmaceutically acceptable esters or pharmaceutically acceptable salts thereof | UNIV KINGSTON (CH) | 2008-11-26 | — | — | CN | claimed |
| US-6562836-B1 | Islet amyloid polypeptide (IAPP) is known to be capable of forming fibrils which are deposited in the pancreas of patients wtih type II diabetes | QUEEN'S UNIVERSITY OF KINGSTON (CA) | 2003-05-13 | — | — | US | claimed |
| US-7786174-B2 | Methods and compounds for inhibiting amyloid deposits | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2010-08-31 | — | — | US | disclosed |
| US-20080227767-A1 | Administering a compound that inhibits islet amyloid polypeptide-associated amyloid deposition, e.g., 8-hydroxy-5-quinolinesulfonic acid, sodium cyclohexylsulfamate, or octahydroisoquinolinyl-N-propanesulfonic acid; antidiabetic agents | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-09-18 | — | — | US | disclosed |
| US-7393875-B2 | Reducing islet amyloid polypeptide (IAPP) associated deposit; type II diabetes | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-07-01 | — | — | US | disclosed |
| US-4235809-A | α-Amino phosphonic acids | PETROLITE CORPORATION (US) | 1980-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227767-A1 | Administering a compound that inhibits islet amyloid polypeptide-associated amyloid deposition, e.g., 8-hydroxy-5-quinolinesulfonic acid, sodium cyclohexylsulfamate, or octahydroisoquinolinyl-N-propanesulfonic acid; antidiabetic agents | IAPP, APP, AMY2A | ACP3 905/4885TSHR 3800/4885NPSR1 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.